Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.91 USD

0.91
1,185,513

-0.01 (-1.22%)

Updated Oct 18, 2019 03:56 PM ET

Add to portfolio

1-Strong Buy 1        

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | D Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Reata (RETA) Jumps: Stock Rises 5. 6%

Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AVEO RETA

Zacks Equity Research

AVEO (AVEO) Upgraded to Strong Buy: What Does It Mean for the Stock?

AVEO (AVEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVEO

Ekta Bagri

Renal Cell Carcinoma Space in Focus: Some Key Developments

The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.

MRK BMY RHHBY PFE AVEO EXEL

Zacks Equity Research

AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?

AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVEO

Zacks Equity Research

AVEO Surges on Favorable Updated OS Results on RCC Drug

AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.

AZN BMY BAYRY AVEO

Zacks Equity Research

Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus

Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.

AVEO XLRN ALXN HZNP AMGN

Zacks Equity Research

AVEO (AVEO) Up 0.2% Since Last Earnings Report: Can It Continue?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AVEO

Zacks Equity Research

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag

AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.

BMY AZN BAYRY AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 66.67% and -60.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why

AVEO Pharmaceuticals (AVEO) suffers a major setback as it delays the NDA filing for Fotivda in the United States.

AZN BMY BAYRY AVEO

Zacks Equity Research

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO

Zacks Equity Research

AVEO (AVEO) Down 19.9% Since Last Earnings Report: Can It Rebound?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AVEO

Zacks Equity Research

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark

AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.

BAYRY BMY AZN AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark

AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.

AZN BAYRY BMY AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -20.00% and 117.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AVEO Pharmaceuticals (AVEO) closed at $0.91, marking a -1.42% move from the previous day.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?

During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.

AZN AVEO ADRO GILD

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

AVEO Pharmaceuticals (AVEO) closed at $0.92 in the latest trading session, marking a -0.87% move from the prior day.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.

BAYRY AZN AVEO PDLI

Zacks Equity Research

Will AVEO Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

AVEO Pharmaceuticals (AVEO) closed at $1 in the latest trading session, marking a -1.96% move from the prior day.

AVEO